Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jaroslav Goldman

Internal Medicine Chicago, IL Medical Doctor

NPI 1639140403 CMS profile 637442

6420 N. California Ave., Chicago, IL 60645

Open in the dashboard

General payments

$5,981

323 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jaroslav Goldman of Chicago, IL is reported in the CMS Open Payments database as having received $5,981 across 323 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $388 18
2023 General $549 26
2022 General $810 40
2021 General $1,414 76
2020 General $909 49
2019 General $1,911 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaroslav Goldman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jaroslav Goldman were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jaroslav Goldman Internal Medicine median Middle half National median
2019 $1,911 $159 $48–$570 $163
2020 $909 $119 $33–$402 $114
2021 $1,414 $135 $37–$521 $132
2022 $810 $141 $42–$496 $149
2023 $549 $149 $45–$519 $160
2024 $388 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $815 37 payments
  2. Janssen Pharmaceuticals, Inc $814 40 payments
  3. AstraZeneca Pharmaceuticals LP $700 41 payments
  4. Amarin Pharma Inc. $530 28 payments
  5. Pfizer Inc. $408 19 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $398 26 payments
  7. GlaxoSmithKline, LLC. $308 15 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $250 14 payments
  9. Novo Nordisk Inc $228 11 payments
  10. Sunovion Pharmaceuticals Inc. $220 12 payments
  11. Other $1,312 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,969 321 payments
  2. Education $12 2 payments
Products named General payments · program years 2019–2024
  1. XARELTO $691 33 payments
  2. ELIQUIS $353 16 payments
  3. Vascepa $346 18 payments
  4. CREON $324 15 payments
  5. TRULANCE $299 20 payments
  6. SYMBICORT $297 17 payments
  7. INVOKANA $295 15 payments
  8. LINZESS $290 12 payments
  9. TRELEGY ELLIPTA $276 13 payments
  10. JARDIANCE $229 13 payments
  11. Other $3,927 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 194 drugs

Part D claims

17,756

Median for Internal Medicine: 777

Drug cost

$1,590,852

Median for Internal Medicine: $73,373

Branded share of claims

22.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 548 $336,569
Creon Lipase/Protease/Amylase Brand 216 $197,906
Trulance Plecanatide Brand 176 $109,571
Tradjenta Linagliptin Brand 112 $72,763
Linzess Linaclotide Brand 113 $69,554
Januvia Sitagliptin Phosphate Brand 91 $58,828
Vascepa Icosapent Ethyl Brand 120 $50,482
Gemtesa Vibegron Brand 82 $47,057
Xarelto Rivaroxaban Brand 72 $47,021
Jardiance Empagliflozin Brand 86 $46,667

The 10 drugs with the highest cost, of 194 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$106,244

Of which drugs: $2,820

Medicare patients

556

Average age 82

Services billed

2,625

363 women, 193 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 56%
Depression 44%
Ischemic heart disease 43%
Heart failure 42%
Chronic kidney disease 36%
Alzheimer's or dementia 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 17 38 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $53
$53 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $38
$38 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $35
$35 — —
LINZESS
  • AbbVie, Inc. $28
$28 113 —
CREON
  • AbbVie, Inc. $28
$28 216 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record